Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05151172 · ClinicalTrials.gov registry record · NA
EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial)
A NA study of Acute Ischemic Stroke, sponsored by Dr. Michael D Hill.
- Active
- Registry status
- NA
- Development phase
- 530
- Enrollment target
- 20
- Study locations
NCT05151172: Active NA study of Acute Ischemic Stroke, sponsored by Dr. Michael D Hill.
NCT05151172 is a NA study of Acute Ischemic Stroke that is active but no longer recruiting, run by Dr. Michael D Hill. The registered enrollment target is 530 participants, above the 331-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (60% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05151172, a NA study of Acute Ischemic Stroke, is active but no longer recruiting, sponsored by Dr. Michael D Hill.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 530 participants
- Enrollment target
- 20
- Study locations
Study Summary
Stroke occurs when a blood clot causes a blockage in a blood vessel (artery) within the brain. This type of stroke is called an ischemic stroke and carries a high risk of disability or death. Stroke must be treated very fast. Any delay of even 10 minutes can result in the difference between an independent and a disabled outcome, and in some cases between life and death. Endovascular therapy (EVT) or Thrombectomy is a procedure to remove the blood clot (thrombus) from a blood vessel to reopen it (recanalization). Patients are likely to benefit from a thrombectomy procedure when it is performed in a larger blood vessel. Currently it is not known if thrombectomy procedure will benefit the patients presenting with the stroke that has been caused by a blood clot in a medium sized blood vessel (medium vessel occlusion, MeVO). This trial will enrol patients diagnosed with acute stroke due to a clot in the medium sized vessel. The patients will be randomized within 12 hours of their symptom onset to either standard of care or standard of care plus thrombectomy procedure. The participation will last for 12 months Escape MeVO coordinating centre is located at the University of Calgary. There will be up to 75 sites. We will be recruiting a total of 530 patients.
Conditions Studied
Interventions
- DEVICE endovascular thrombectomy (EVT)
- OTHER Standarad medical care
Study Locations (20)
Florida
- Baptist Health Medical Centre - Jacksonville
- Mayo Clinic - Jacksonville
- Tampa General Hospital - Tampa
Ohio
- The Ohio State University - Columbus
- Ohio Health (Columbus ORI) - Columbus
- University of Toledo - Toledo
California
- Sutter Health - San Francisco
- Providence Little company of Mary - Torrance
Illinois
- Northwestern Medicine - Chicago
- Rush university Medical Centre - Chicago
Arkansas
- Baptist Health Medical Center - Little Rock
Connecticut
- Yale School of Medicine - New Haven
Kansas
- University of Kansas Medical Center - Kansas City
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What the registry record for NCT05151172 still lists
NCT05151172 is an interventional study that assigns participants to a tested intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap, above the 331-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (60% higher).
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which endovascular thrombectomy (EVT) is the first listed.
NCT05151172 names 20 study sites across 14 states, led by Florida, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT05151172 about?
NCT05151172 is a clinical study titled "EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial)". Stroke occurs when a blood clot causes a blockage in a blood vessel (artery) within the brain. This type of stroke is called an ischemic stroke and carries a high risk of disability or death. Stroke must be treated very fast. Any delay of even 10 minutes can result in the difference between an indep...
What is the current status of trial NCT05151172?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 530 participants. The study started on 2022-04-15. Estimated completion is 2026-06-30.
What conditions does trial NCT05151172 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT05151172?
The interventions under investigation include: endovascular thrombectomy (EVT) (DEVICE), Standarad medical care (OTHER).
Who is sponsoring clinical trial NCT05151172?
This trial is sponsored by Dr. Michael D Hill, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05151172 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05151172's enrollment target sits among peer trials
530 6th of 25 higher than 20 of 25 other Acute Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke
RECRUITING · NA
-
Hyperbaric Oxygen Therapy in Acute Ischemic Stroke Ischemic Stroke Recovery (Pro00061930)
RECRUITING · NA
-
The Pivotal Study of RapidPulseTM Aspiration System
RECRUITING · NA
-
An EFS to Evaluate the CGuard Prime™ Carotid Stent in Acute Ischemic Stroke
ACTIVE NOT RECRUITING · NA
-
Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI
ACTIVE NOT RECRUITING · NA
-
Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06646276 · 530 participants · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- NCT06703476 · 530 participants · Phase 3
A Study of Surgical Techniques During Cystectomy
- NCT06880744 · 530 participants · Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
- NCT07138040 · 530 participants · NA
Re-Engaging AYA Survivors in Cancer-Related Healthcare
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI